Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a leading biopharmaceutical company based in China, focuses on innovative drug discovery and development. Founded in 2015, the company has rapidly established itself in the biotechnology sector, with its headquarters in Beijing and operational reach across major regions in China. Specialising in monoclonal antibodies and gene editing technologies, Biocytogen is renowned for its unique animal models that facilitate advanced preclinical research. The company’s commitment to innovation has positioned it as a key player in the global biopharmaceutical landscape, with notable achievements in therapeutic development and collaborations with various research institutions. With a strong emphasis on quality and scientific excellence, Biocytogen continues to drive advancements in the industry, contributing significantly to the future of healthcare solutions.
DitchCarbon Score
How does Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s score of 27 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s reported carbon emissions
In 2023, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. reported total carbon emissions of approximately 23,506,310 kg CO2e from Scope 1 and 240 kg CO2e from Scope 2, while Scope 3 emissions were about 58,000 kg CO2e, primarily from purchased goods and services. This represents a significant increase in emissions compared to 2022, where the company recorded approximately 19,472,490 kg CO2e for both Scope 1 and Scope 2, with no reported Scope 3 emissions. Despite the increase in emissions, Biocytogen has not disclosed any specific reduction targets or initiatives aimed at mitigating their carbon footprint. The company has reported greenhouse gas emission intensities of 240 kg CO2e per square metre and 0.00058 kg CO2e per RMB 1,000 expenditure, indicating their ongoing commitment to monitoring emissions relative to operational metrics. As of now, Biocytogen has not established any formal climate pledges or targets aligned with the Science Based Targets initiative (SBTi), which suggests a potential area for future development in their sustainability strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 19,472,490 | 00,000,000 |
| Scope 2 | 19,472,490 | 000 |
| Scope 3 | - | 000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
